{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:05Z","timestamp":1786119125328,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Optimal nutritional therapy for pancreaticoduodenectomy (PD) has been debated; however, little is known about key points of pancreatin enteric-coated capsule administration, a critical component of the PD treatment regimen. Patients often report elevations in tablet platoon and steatorrhea, and steatorrhea may adversely affect nutritional therapy for PD. Herein, we report a case of individualized pharmaceutical care for a patient after PD with trypsin replacement nutritional therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns and diagnosis:<\/jats:title>\n                    <jats:p>After PD with trypsin replacement nutritional therapy, the patient developed acute steatorrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>Individualized pharmaceutical care was provided by clinical pharmacists to address intolerance to pancreatin enteric-coated capsules following PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The clinical pharmacist\u2019s integration into the patient\u2019s treatment plan enhanced pharmacotherapy optimization, especially through pharmacokinetic monitoring and interventions related to nutritional therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lesson:<\/jats:title>\n                    <jats:p>Pharmaceutical care by clinical pharmacists aids in ensuring the safety and efficacy of drugs and nutritional treatment. Clinical pharmacists should be members of the nutrition support team.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000030209","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:06:01Z","timestamp":1661853961000},"page":"e30209","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Individualized pharmaceutical care for a patient after pancreaticoduodenectomy with trypsin replacement nutritional therapy: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-0721","authenticated-orcid":false,"given":"Song","family":"Zhang","sequence":"first","affiliation":[{"name":"The First People\u2019s Hospital of Guangyuan, Guangyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Tan","sequence":"additional","affiliation":[{"name":"The People\u2019s Hospital of Nanchuan, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-0059","authenticated-orcid":false,"given":"Hanjun","family":"He","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Guangyuan, Guangyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"147997311990061404143044","DOI":"10.1177\/1479973119900612","article-title":"Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy.","volume":"17","author":"Trapnell","year":"2020","journal-title":"Chron Respir Dis"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/nu14030680","article-title":"Intestinal absorption of lipids using a pancreatic enzyme-free nutritional supplement in patients with cystic fibrosis: a randomized, double-blind, crossover pilot trial.","volume":"14","author":"Barto","year":"2022","journal-title":"Nutrients"},{"key":"R3-20250707","first-page":"95","article-title":"Research progress of standardized pharmaceutical care model.","volume":"29","author":"Min","year":"2020","journal-title":"China Pharmaceutical Co"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.surg.2018.05.040","article-title":"Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS).","volume":"164","author":"Gianotti","year":"2018","journal-title":"Surgery"},{"key":"R5-20250707","first-page":"819","article-title":"Research progress of total pancreatectomy.","volume":"9","author":"Yuanchong","year":"2019","journal-title":"Chin J General Surg"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12325-010-0085-7","article-title":"CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.","volume":"27","author":"Kuhn","year":"2010","journal-title":"Adv Ther"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11592990-000000000-00000","article-title":"Administration of CREON(R) pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.","volume":"31","author":"Shlieout","year":"2011","journal-title":"Clin Drug Investig"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12325-010-0085-7","article-title":"CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.","volume":"27","author":"Kuhn","year":"2010","journal-title":"Adv Ther"},{"key":"R9-20250707","first-page":"2346","article-title":"Study on disintegration time limit of four enteric-soluble capsules.","volume":"15","author":"Xiaohong","year":"2008","journal-title":"Modern Med Health"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2036.2007.03563.x","article-title":"In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.","volume":"27","author":"Aloulou","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2036.1996.55197000.x","article-title":"In vitro dissolution profiles of enteric-coated microsphere\/microtablet pancreatin preparations at different pH values.","volume":"10","author":"Gan","year":"1996","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:49:00Z","timestamp":1786038540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":11,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030209","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}